Pitavastatin promising for reducing risk of cardiovascular disease in people with HIV: REPRIEVE substudy
USA: A recent analysis of the REPRIEVE trial revealed pitavastatin to be promising in reducing noncalcified coronary plaque as well as markers of lipid oxidation and arterial inflammation among people with HIV at low to moderate cardiovascular (CV) risk. The study findings were published online in JAMA Cardiology. The substudy of the REPRIEVE randomized clinical […]